» Articles » PMID: 22028441

Aromatase Deficiency Confers Paradoxical Postischemic Cardioprotection

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2011 Oct 27
PMID 22028441
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The conventional view is that estrogen confers female cardioprotection. Estrogen synthesis depends on androgen availability, with aromatase regulating conversion of testosterone to estradiol. Extragonadal aromatase expression mediates estrogen production in some tissues, but a role for local steroid conversion has not yet been demonstrated in the heart. This study's goal was to investigate how aromatase deficiency influences myocardial function and ischemic resilience. RT-PCR analysis of C57Bl/6 mouse hearts confirmed cardiac-specific aromatase expression in adult females. Functional performance of isolated hearts from female aromatase knockout (ArKO) and aromatase wild-type mice were compared. Left ventricular developed pressures were similar in aerobic perfusion, but the maximal rate of rise of ventricular pressure was modestly reduced in ArKO hearts (3725 ± 144 vs. 4272 ± 154 mm Hg/sec, P < 0.05). After 25 min of ischemia, the recovery of left ventricular developed pressure was substantially improved in ArKO (percentage of basal at 60 min of reperfusion, 62 ± 8 vs. 30 ± 6%; P < 0.05). Hypercontracture was attenuated (end diastolic pressure, 25 ± 5 vs. 51 ± 1 mm Hg; P < 0.05), and lactate dehydrogenase content of coronary effluent was reduced throughout reperfusion in ArKO hearts. This was associated with a hyperphosphorylation of phospholamban and a reduction in phosphorylated Akt. Immediately after reperfusion, ArKO hearts exhibited increased incidence of ventricular premature beats (194 ± 70 vs. 46 ± 6, P < 0.05). These observations indicate more robust functional recovery, reduced cellular injury, and modified cardiomyocyte Ca(2+) handling in aromatase-deficient hearts. Our findings indicate that androgen-to-estrogen conversion may be of pathophysiologic importance to the heart and challenge the notion that estrogen deficiency is deleterious. These studies suggest the possibility that aromatase suppression may offer inotropic benefit in the acute ischemia/reperfusion setting with appropriate arrhythmia management.

Citing Articles

Association between Low Serum Testosterone Levels and All-cause Mortality in Patients With Cardiovascular Disease: A Study Based on the NHANES Database.

Jiang R, Wang Y Cardiovasc Toxicol. 2025; 25(4):604-613.

PMID: 40050519 DOI: 10.1007/s12012-025-09973-7.


Exposure to nitrate and nitrite disrupts cardiovascular development through estrogen receptor in zebrafish embryos and larvae.

Saputra F, Hu S, Kishida M Fish Physiol Biochem. 2024; 50(6):2165-2178.

PMID: 39026114 DOI: 10.1007/s10695-024-01381-y.


Mechanisms and implications of sex differences in cardiac aging.

Yusifov A, Woulfe K, Bruns D J Cardiovasc Aging. 2022; 2.

PMID: 35419571 PMC: 9004711. DOI: 10.20517/jca.2022.01.


Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial.

Islam R, Bell R, Handelsman D, McNeil J, Nelson M, Reid C Lancet Healthy Longev. 2022; 3(2):e109-e118.

PMID: 35252940 PMC: 8896500. DOI: 10.1016/S2666-7568(22)00001-0.


Sexual dimorphism in cardiac remodeling: the molecular mechanisms ruled by sex hormones in the heart.

Ferreira C, Trindade F, Ferreira R, Neves J, Leite-Moreira A, Amado F J Mol Med (Berl). 2021; 100(2):245-267.

PMID: 34811581 DOI: 10.1007/s00109-021-02169-w.